Login
$ORKA
$99.24 -$6.11 (5.8%) Live

$ORKA 8-K SEC Filings

Filed On Filing
26 Oct 2026 8-K: Regulation FD Disclosure; Other Events

©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - B Interim Data ORKA - 001 Phase 2b trial in psoriasis October 26, 2026

24 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you the position of Chief Commercial Officer (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by yo...

10 Aug 2026 8-K: Results of Operations and Financial Condition

EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2026, Oruka Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together wit...

01 Jun 2026 8-K: Other Events

This First Amendment to IL-23 License Agreement (this “First Amendment”) is dated as of May 29, 2026 (the “Amendment Effective Date”) and is entered into by and between Paragon Therapeutics, Inc., a corporation organized under the laws o...

30 Apr 2026 8-K: Results of Operations and Financial Condition; Other Events

Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC, (“TD Securities”), Goldman Sachs & Co. LLC (“Goldman Sac...

27 Apr 2026 8-K: Regulation FD Disclosure; Other Events

©2026 Oruka Therapeutics ©2026 ORUKA THERAPEUTICS EVERLAST - A Interim Data ORKA - 001 Phase 2a trial in psoriasis April 27, 2026

11 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Re: Appointment to Oruka Therapeutics, Inc. Board of Directors

22 Sep 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 17, 2025, by and among Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreeme...

01 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you the position of Chief Operating Officer (the “Role”) pursuant to this letter agreement (the “Agreement”). Your employment with the Company commenced on Marc...

03 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2025, Oruka Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together wit...

05 Feb 2025 8-K: Entry into a Material Definitive Agreement

IL-17A/F (ORKA-002) License Agreement – Paragon Therapeutics, Inc.

19 Dec 2024 8-K: Entry into a Material Definitive Agreement

IL-23 (ORKA-001) License Agreement – Paragon Therapeutics, Inc.

18 Nov 2024 8-K: Submission of Matters to a Vote of Security Holders

On November 14, 2024, Oruka Therapeutics, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Special Meeting, toge...

14 Nov 2024 8-K: Other Events

To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.

04 Oct 2024 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of the Board of Directors (the “Board”) of Oruka Therapeutics, Inc. (the “Company”), I am pleased to offer you a continuing position as Chief Executive Officer of the Company (“CEO”) and as a member of the Board pursuant to thi...

13 Sep 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential.

05 Sep 2024 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more

Defined terms included below shall have the same meaning as terms defined and included in the Company’s definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 22, 2024.

27 Aug 2024 8-K: Other Events

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

23 Aug 2024 8-K: Submission of Matters to a Vote of Security Holders; Other Events

Westminster, CO, August 23, 2024 – ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common sto...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support